Raynaud’s Phenomenon: A Multidisciplinary Problem

Оглы, Алекперов Ризван Таир

doi:10.18786/2072-0505-2014-35-94-100

Cited by 2 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Феномен Рейно (ФР) характеризуется эпизодами (атаками, приступами) вазоспазма периферических сосудов микроциркуляторного русла на пальцах рук, ног и ассоциирован преимущественно с системными заболеваниями соединительной ткани, наиболее часто -с системной склеродермией (ССД; 96 %), системной красной волчанкой (СКВ; 31 %) и смешанным заболеванием соединительной ткани (86 %) [1,2]. Атака ФР сопровождается онемением, болью, покалыванием [1]. Субъективно пациентов беспокоит изменение окраски кожи кистей и/или стоп -побеление, посинение, покраснение вследствие спазма дигитальных артерий и дальнейшего восстановления кровотока [1].…”

unclassified

“…Атака ФР сопровождается онемением, болью, покалыванием [1]. Субъективно пациентов беспокоит изменение окраски кожи кистей и/или стоп -побеление, посинение, покраснение вследствие спазма дигитальных артерий и дальнейшего восстановления кровотока [1]. В практике используется клинически валидированная шкала -счет состояния Рейно (Raynaud's Condition Score, RCS) [3].…”

unclassified

“…Согласно данным Алекперова Р.Т., ДР и ДЯ являются результатом прогрессирования дигитальной ишемии и вносят неоспоримый вклад в утяжеление течения ФР [1]. В нашем исследовании показано, что кроме данных проявлений ишемии вклад в выраженность ФР вносят также интенсивность боли при атаке Рейно и длительность РЗ.…”

unclassified

See 2 more Smart Citations

Evaluation of clinical efficacy of prostanoid therapy for Raynaud’s phenomenon in rheumatic diseases

Bagautdinova¹,

Рифкатовна²,

Гайсин

et al. 2018

Kazan Med J

View full text Add to dashboard Cite

Aim. On the basis of clinical manifestations of Raynaud’s phenomenon (RP) to determine the RP expression level and to evaluate the long-term efficacy of treatment of RP in patients with rheumatic diseases (RD) with iloprost and alprostadil. Methods. Treatment for indications with prostanoids (intravenous iloprost, alprostadil or their combinations) was administered to 40 patients with secondary RP in RD. During 3-year follow up, clinical instrumental parameters (frequency of attacks of Raynaud's, digital ulcers (DU) formation, pain intensity on visual analogue scale (VAS) were evaluated. The control group included 30 patients with RP in RD who did not receive prostanoid therapy. The method of factor analysis was used to determine the index of generalized expression of RP, on the basis of which the expression levels of the RP were determined. Results. The “expression of RP” scale revealed in the course of factor analysis as an indicator of generalized manifestation of RP, is the average value of two subscales, the first one of which consisted of four indices - “digital ulcer”, “digital pitting scars”, “phalange amputation” and “Raynaud's attack frequency”, and the second one included “intensity of pain”, “duration of illness”, “whitening of fingers”. Verification of the correlation revealed during the study of subscales, showed its reliability (r = 0.294, p = 0.053). The final expression of RP was 1.51 ± 0.86. The low level of RP expression had values up to 0.65, high - over 2.37. When included in the study, a high level of RP expression was defined in 16 (22.9 %) patients, medium - in 43 (61.4 %), low - in 11 (15.7 %). The use of iloprost in the treatment of RP was effective for healing of DU and a statistically significant decrease of the generalized expression of RP from 2.25 [1; 3] to 1.75 [1; 2] (p = 0.012) was observed. On alprostadil treatment, statistically significantly decreased frequency of attacks from multiple daily (more than once a day) to once a month and reduced numbness during RP attack were observed as well as a decrease of the level of generalized index of RP expression from 1.26 ± 0.71 to 0.97 ± 0.57 (р = 0.038). The combination of prostanoids had a contradictory clinical effect: the pain and frequency of RP attacks decreased, but the formation of DU and new cases of amputations of phalanges were registered, the treatment had no effect on the value of RP expression. Conclusion. Based on the clinical manifestations of RP, a generalized index of RP severity was identified and the levels of RP severity were determined. Treatment with iloprost and alprostadil has a significant effect on reducing the clinical manifestations of RP with a corresponding decrease in its severity.

show abstract

unclassified

See 1 more Smart Citation

Evaluation of clinical efficacy of prostanoid therapy for Raynaud’s phenomenon in rheumatic diseases

Bagautdinova¹,

Рифкатовна²,

Гайсин

et al. 2018

Kazan Med J

View full text Add to dashboard Cite

show abstract

Clinical and Neurophysiological Parallels of the Brachial Plexopathy in the Structure of Neurogenic Thoracic Outlet Syndrome

et al. 2022

View full text Add to dashboard Cite

The aim: Was assessment of the neurophysiological data and features of clinical picture in patients with neurogenic thoracic outlet syndrome (TOS). Materials and methods: 103 patients with upper extremity pain and/or paresthesia or hypotrophy, or a combination of these symptoms were examined. The examination algorithm included: cervical spine radiography, cervical spine and brachial plexuses magnetic resonance imaging (MRI), upper extremity soft tissues and vessels ultrasonic examination, stimulation electroneuromiography with F-waves registration. Results: Neurogenic TOS was diagnosed in 29 patients. A significant relationship between the following complaints and neurophysiological parameters was observed: pain, numbness during physical activity and decreased medial anrebrachial cutaneous nerve response amplitude by ≥25% compared to the contralateral side; hypothenar hypotrophy and decrease of ulnar nerve motor/sensory response amplitude; the 4-5th fingers hypoesthesia and decrease of ulnar nerve sensory response amplitude. Conclusions: Medial antebrachial cutaneous nerve amplitudes asymmetry indices of ≥25% or lack of response may be considered to be a marker of true neurogenic TOS.

show abstract

Raynaud’s Phenomenon: A Multidisciplinary Problem

Cited by 2 publications

References 19 publications

Evaluation of clinical efficacy of prostanoid therapy for Raynaud’s phenomenon in rheumatic diseases

Evaluation of clinical efficacy of prostanoid therapy for Raynaud’s phenomenon in rheumatic diseases

Clinical and Neurophysiological Parallels of the Brachial Plexopathy in the Structure of Neurogenic Thoracic Outlet Syndrome

Contact Info

Product

Resources

About